DE69815090T2 - Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen - Google Patents

Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen Download PDF

Info

Publication number
DE69815090T2
DE69815090T2 DE69815090T DE69815090T DE69815090T2 DE 69815090 T2 DE69815090 T2 DE 69815090T2 DE 69815090 T DE69815090 T DE 69815090T DE 69815090 T DE69815090 T DE 69815090T DE 69815090 T2 DE69815090 T2 DE 69815090T2
Authority
DE
Germany
Prior art keywords
group
benzyl
methylpiperidine
dimethoxy
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815090T
Other languages
German (de)
English (en)
Other versions
DE69815090D1 (de
Inventor
L. Sharon ROGERS
T. Lawrence FRIEDHOFF
J. Paul TISEO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE69815090D1 publication Critical patent/DE69815090D1/de
Application granted granted Critical
Publication of DE69815090T2 publication Critical patent/DE69815090T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69815090T 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen Expired - Lifetime DE69815090T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3983297P 1997-03-03 1997-03-03
US39832P 1997-03-03
PCT/IB1998/000508 WO1998039000A1 (en) 1997-03-03 1998-03-03 Use of cholinesterase inhibitors to treat disorders of attention

Publications (2)

Publication Number Publication Date
DE69815090D1 DE69815090D1 (de) 2003-07-03
DE69815090T2 true DE69815090T2 (de) 2004-02-19

Family

ID=21907565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815090T Expired - Lifetime DE69815090T2 (de) 1997-03-03 1998-03-03 Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen

Country Status (12)

Country Link
US (2) US6455544B1 (OSRAM)
EP (1) EP0971713B1 (OSRAM)
JP (1) JP4095676B2 (OSRAM)
AT (1) ATE241358T1 (OSRAM)
AU (1) AU743609B2 (OSRAM)
CA (1) CA2282654C (OSRAM)
DE (1) DE69815090T2 (OSRAM)
DK (1) DK0971713T3 (OSRAM)
ES (1) ES2200313T3 (OSRAM)
NZ (1) NZ337515A (OSRAM)
PT (1) PT971713E (OSRAM)
WO (1) WO1998039000A1 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0971713T3 (da) * 1997-03-03 2003-09-22 Eisai Co Ltd Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
WO2001066114A1 (en) 2000-03-03 2001-09-13 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
EP1764101A1 (en) * 2000-03-03 2007-03-21 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
AU2003298514A1 (en) * 2002-05-17 2004-05-04 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070053976A1 (en) * 2002-05-17 2007-03-08 Eisai R & D Management Co., Ltd. Novel combination of drugs as antidepressant
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) * 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
WO2005105742A1 (ja) 2004-04-28 2005-11-10 Eisai R&D Management Co., Ltd. １－ベンジル－４－［（５，６－ジメトキシ－１－インダノン）－２－イル］メチルピペリジンおよびその塩酸塩の製造法
US7718674B2 (en) * 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
WO2006037047A2 (en) * 2004-09-27 2006-04-06 Bridge Pharma, Inc. The r-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
AU2006209216A1 (en) 2005-01-25 2006-08-03 Galenea Corp Substituted arylamine compounds and their use as 5-HT6 modulators
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
AU2006300492B2 (en) * 2005-10-14 2011-08-25 Eisai R & D Management Co., Ltd. Process for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine or hydrochloride thereof
JP2009515945A (ja) * 2005-11-14 2009-04-16 メディチェム エセ．ア． 塩酸ドネペジルの調製に有用な中間体およびその新規な多形の改善された合成および調製
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2008011161A2 (en) * 2006-07-21 2008-01-24 Bridge Pharma, Inc. Dermal anesthetic compounds
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
JP5237112B2 (ja) * 2006-12-01 2013-07-17 日東電工株式会社 経皮吸収製剤
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
KR100914691B1 (ko) * 2007-08-10 2009-08-28 주식회사유한양행 도네페질 또는 그의 제조용 중간체의 제조방법
RU2483729C2 (ru) * 2008-05-30 2013-06-10 Нитто Денко Корпорейшн Чрескожно абсорбируемый препарат
RU2481826C2 (ru) * 2008-05-30 2013-05-20 Нитто Денко Корпорейшн Содержащий донепезил адгезивный препарат и упаковка для него
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013166037A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of eye disorders
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
WO2014152013A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK4036094T3 (da) 2014-04-30 2026-03-23 Univ Columbia Erstattede 4-fenylpiperidiner, deres fremstilling og anvendelse
KR101732776B1 (ko) * 2014-10-08 2017-05-04 영남대학교 산학협력단 신규한 인데노 피리디니움 유도체 화합물 및 이의 제조방법
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5064858A (en) * 1988-08-17 1991-11-12 Spectrum Pharmaceutical Corporation Protected complex of procaine for the treatment of symptoms from narcotics addiction, tinnitus and Alzheimer's disease
EP0840610A1 (en) * 1995-07-14 1998-05-13 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
ES2188946T3 (es) 1996-06-07 2003-07-01 Eisai Co Ltd Polimorfos de clorhidrato de donepecil y proceso de fabricacion de los mismos.
DK0971713T3 (da) * 1997-03-03 2003-09-22 Eisai Co Ltd Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser

Also Published As

Publication number Publication date
CA2282654A1 (en) 1998-09-11
JP2001515480A (ja) 2001-09-18
US7105540B2 (en) 2006-09-12
EP0971713B1 (en) 2003-05-28
NZ337515A (en) 2002-07-26
AU7321598A (en) 1998-09-22
US20030055040A1 (en) 2003-03-20
DE69815090D1 (de) 2003-07-03
PT971713E (pt) 2003-09-30
EP0971713A1 (en) 2000-01-19
ATE241358T1 (de) 2003-06-15
CA2282654C (en) 2009-02-03
AU743609B2 (en) 2002-01-31
DK0971713T3 (da) 2003-09-22
US6455544B1 (en) 2002-09-24
JP4095676B2 (ja) 2008-06-04
ES2200313T3 (es) 2004-03-01
WO1998039000A1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
JP4095676B2 (ja) 注意障害を治療するためのコリンエステラーゼ阻害剤の使用
DE3855028T2 (de) 1,4-Substituierte Piperidine als Acetylcholinesterase Inhibitoren und ihre Verwendung zur Behandlung von Alzheimer's Erkrankung
DE60124730T2 (de) Neue methoden unter verwendung von cholinesteraseinhibitoren
DE69838179T2 (de) Chronische bolusgabe von d-threo methylphenidat
DE69535234T2 (de) Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE69903750T2 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
DE69507419T2 (de) Verwendung von einem Tetrahydropyridin- oder azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
WO2002020521A1 (de) Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems
DE69825605T2 (de) Behandlung der schizophrenie und der psychose
DE69908421T2 (de) Pharmazeutische zusammensetzung enthaltend eine kombination der dextro- und laevo-isomeren von sotalol
DE69326459T2 (de) Wirkstoffe zur behandlung von suchterkrankungen
JPH0354922B2 (OSRAM)
DE2362958A1 (de) N-substituiertes pyridon und verfahren zur herstellung von pyridon-verbinnungen
EP0003602B1 (de) Pyrrolidin-Derivate zur Anwendung als therapeutische Wirkstoffe und diese enthaltende Arzneimittel
DE68907392T2 (de) Dysmnesie modifizierende Arzneimittel.
DE69815518T2 (de) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide als 5-ht2 rezeptor antagonist
DD202539A5 (de) Verfahren zur herstellung von 1-(3-hydroxy-4-methoxybenzoyl)-3-hydroxy-2-pyrolidinon
DE60216776T2 (de) Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
US5434177A (en) Imidazoles for the treatment of age-related cognitive disorders and alzheimer
EP1152762A1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE3889043T2 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE69032046T2 (de) Tetrahydroisochinolinylcarbamate von 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo [2,3-b] indol
DE69919789T2 (de) Loratadin zur Verwendung als Antiarrhythmikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition